Trading Signals: INO Stock Price Prediction and Forecast (Thu. May. 1, 2003 - Fri. May. 13, 2022)(Inovio Pharmaceuticals, Inc. )
| INO latest price $22.4000 (-5.41%) ($21.7600 - $25.6000) on Mon. May. 24, 2004. | |
| | Trend Analysis and Forecast | | | | Average Daily Percentage Swing | 3.49% (three month average) | | RSI | 35 | | Latest Price | $22.4000(-5.41%) | | Stocks Behave Similarly | Similar Stock List | | Daily Trend | INO declines -1.4% a day on average for past five trading days. | | Weekly Trend | INO declines -5.3% a week on average for past two weeks. | | Market Behavior | Normal for large cap. Normal for small cap. | | Correlated ETFs | Broad market will support INO advance at 0% a week (0% probability)
EWY(4%) EEM(3%) XLU(3%) EWG(2%) EWP(2%) | | Factors Impacting INO price | INO will decline at least -1.745% in a week (0% probabilities).
SHY(-2%) LQD(-2%) TLT(-1%) TIP(-1%) REMX(-1%) | | | | | | | | Relative Volatility | (options are extremely cheap) | | | | | Market Trend Strength | -1.745% (StdDev 3.49%) | | Hourly BBV | 0 () | | Intraday Trend | -12.5% | | | | | |
|
| 1 - 5 Day Possible Target | $14.97(-33.17%) | | Resistance Level | $24.64 | | 5 Day Moving Average | $23.42(-4.36%) | | 10 Day Moving Average | $23.98(-6.59%) | | 20 Day Moving Average | $24.64(-9.09%) | | To recent high | -21.8% | | To recent low | 0% | | Market Cap | $3.556b | | | | | | |
Inovio Pharmaceuticals, Inc. is a late-stage biotechnology company. It engages in the discovery, development, and commercialization of DNA-based immunotherapies and vaccines. The firm's drug candidates include SynCon immunotherapies which helps break the immune system's tolerance of cancerous cells; and CELLECTRA delivery system which facilitates optimized cellular uptake of the SynCon immunotherapies. The company was founded by David B. Weiner on June 29, 1983 and is headquartered in Plymouth Meeting, PA. June 23 announcement that it had received $71 million from the U.S. Department of Defense (DoD) pertaining to its two Cellectra devices, both of which are used to administer its COVID-19 vaccine candidShares fell sharply in the two-day period following the company's June 30 announcement of interim phase 1 poisitive results for its COVID-19 vaccine candidate.
Inovio plans to begin a phase 2/3 clinical study for INO-4800 this summer assuming it receives the FDA's approval.ate INO-4800. |